Medications for the acute treatment of migraine: new advances and optimization strategies

Xu Xiaonuo, Dong Liang, Zhou Jiying

PDF(518 KB)
PDF(518 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (05) : 577-582. DOI: 10.13406/j.cnki.cyxb.003491
Treatment of paroxysmal diseases and epilepsy in the nervous system

Medications for the acute treatment of migraine: new advances and optimization strategies

Author information +
History +

Abstract

The acute treatment of migraine aims to provide rapid relief of headache and accompanying symptoms and is one of the main methods for the prevention and treatment of migraine. In recent years，new advances have been made in medications for the acute treatment of migraine，with the aim to improve the efficacy and safety of treatment. Excessive use of acute treatment medications and ineffective acute treatment are important risk factors for the chronicity of migraine. Different acute treatment medications may have different effects on the chronicity of migraine. There is still much room for the optimization of migraine acute treatment，and clinicians should develop individualized treatment regimens based on the specific conditions of the patient，so as to improve the efficacy of acute treatment and prevent the chronicity of migraine.This article reviews the current situation and strategies of acute treatment of migraine and the relationship between acute treatment and chronic migraine.

Key words

migraine / acute treatment of migraine / treatment strategies / chronicity of migraine

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Xu Xiaonuo , Dong Liang , Zhou Jiying. Medications for the acute treatment of migraine: new advances and optimization strategies. Journal of Chongqing Medical University. 2024, 49(05): 577-582 https://doi.org/10.13406/j.cnki.cyxb.003491

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Headache Classification Committee of the International Headache Society（IHS）. The International Classification of Headache Disorders，3rd edition[J]. Cephalalgia，2018，38（1）：1-211．
本文引用 [2]
2
Ashina M， Katsarava Z， Do TP，et al. Migraine：epidemiology and systems of care[J]. Lancet，2021，397（10283）：1485-1495．
本文引用 [1]
3
Natoli JL， Manack A， Dean B，et al. Global prevalence of chronic migraine：a systematic review[J]. Cephalalgia，2010，30（5）：599-609．
本文引用 [1]
4
Hovaguimian A， Roth J. Management of chronic migraine[J]. BMJ，2022，379：e067670．
本文引用 [1]
5
Lipton RB， Buse DC， Nahas SJ，et al. Risk factors for migraine disease progression：a narrative review for a patient-centered approach[J]. J Neurol，2023，270（12）：5692-5710．
本文引用 [1]
6
Diener HC， Tassorelli C， Dodick DW，et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults：fourth edition[J]. Cephalalgia，2019，39（6）：687-710．
本文引用 [1]
7
Sacco S， Lampl C， Amin FM，et al. European Headache Federation（EHF） consensus on the definition of effective treatment of a migraine attack and of triptan failure[J]. J Headache Pain，2022，23（1）：133．
本文引用 [1]
8
Ashina M， Buse DC， Ashina H，et al. Migraine：integrated approaches to clinical management and emerging treatments[J]. Lancet，2021，397（10283）：1505-1518．
本文引用 [5]
9
Eigenbrodt AK， Ashina H， Khan S，et al. Diagnosis and management of migraine in ten steps[J]. Nat Rev Neurol，2021，17（8）：501-514．
本文引用 [6]
10
Lipton RB， Kolodner K， Bigal ME，et al. Validity and reliability of the Migraine-Treatment Optimization Questionnaire[J]. Cephalalgia，2009，29（7）：751-759．
本文引用 [1]
11
Bigal ME， Borucho S， Serrano D，et al. The acute treatment of episodic and chronic migraine in the USA[J]. Cephalalgia，2009，29（8）：891-897．
本文引用 [2]
12
Serrano D， Buse DC， Manack Adams A，et al. Acute treatment optimization in episodic and chronic migraine：results of the American Migraine Prevalence and Prevention（AMPP） Study[J]. Headache，2015，55（4）：502-518．
本文引用 [1]
13
Takeshima T， Ueda K， Komori M，et al. Potential unmet needs in acute treatment of migraine in Japan：results of the Overcome（Japan） study[J]. Adv Ther，2022，39（11）：5176-5190．
本文引用 [1]
14
Marmura MJ， Silberstein SD， Schwedt TJ. The acute treatment of migraine in adults：the American headache society evidence assessment of migraine pharmacotherapies[J]. Headache，2015，55（1）：3-20．
本文引用 [2]
15
中国医师协会神经内科医师分会，中国研究型医院学会头痛与感觉障碍专业委员会. 中国偏头痛诊治指南（2022版）[J]. 中国疼痛医学杂志，2022，28（12）：881-898．
The Chinese Physician Association neurologist branch，Chinese Society of Research Hospital Headache and Sensory Disorders Special Committee. Guidelines for diagnosis and treatment of migraine in China_2022 edition）[J]. Chin J Pain Med，2022，28（12）：881-898．
本文引用 [2]
16
Amundsen S， Nordeng H， Nezvalová-Henriksen K，et al. Pharmacological treatment of migraine during pregnancy and breastfeeding[J]. Nat Rev Neurol，2015，11（4）：209-219．
本文引用 [1]
17
Bigal ME， Lipton RB. Excessive opioid use and the development of chronic migraine[J]. Pain，2009，142（3）：179-182．
本文引用 [1]
18
Villalón CM， VanDenBrink AM. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments[J]. Mini Rev Med Chem，2017，17（11）：928-938．
本文引用 [1]
19
Ong JJY， de Felice M. Migraine treatment：current acute medications and their potential mechanisms of action[J]. Neurotherapeutics，2018，15（2）：274-290．
本文引用 [4]
20
de Vries T， Villalón CM， MaassenVanDenBrink A. Pharmacological treatment of migraine：CGRP and 5-HT beyond the triptans[J]. Pharmacol Ther，2020，211：107528．
本文引用 [4]
21
Ferrari MD， Goadsby PJ， Burstein R，et al. Migraine[J]. Nat Rev Dis Primers，2022，8：2．
本文引用 [2]
22
Dodick D， Lipton RB， Martin V，et al. Consensus statement：cardiovascular safety profile of triptans（5-HT agonists） in the acute treatment of migraine[J]. Headache，2004，44（5）：414-425．
本文引用 [1]
23
Wammes-van der Heijden EA， Rahimtoola H， Leufkens HG，et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use[J]. Neurology，2006，67（7）：1128-1134．
24
Roberto G， Piccinni C， D’Alessandro R，et al. Triptans and serious adverse vascular events：data mining of the FDA Adverse Event Reporting System database[J]. Cephalalgia，2014，34（1）：5-13．
25
Diener HC. The risks or lack thereof of migraine treatments in vascular disease[J]. Headache，2020，60（3）：649-653．
本文引用 [1]
26
Olesen J， Diener HC， Schoenen J，et al. No effect of eletriptan administration during the aura phase of migraine[J]. Eur J Neurol，2004，11（10）：671-677．
本文引用 [1]
27
Steiner TJ， Jensen R， Katsarava Z，et al. Aids to management of headache disorders in primary care（2nd edition）[J]. J Headache Pain，2019，20（1）：57．
本文引用 [2]
28
Markowitz S， Saito K， Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater：effect of ergot alkaloids. A possible mechanism of action in vascular headache[J]. Cephalalgia，1988，8（2）：83-91．
本文引用 [1]
29
Tfelt-Hansen PC， Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward[J]. Cephalalgia，2008，28（8）：877-886．
本文引用 [1]
30
Krege JH， Lipton RB， Baygani SK，et al. Lasmiditan for patients with migraine and contraindications to triptans：a post hoc analysis[J]. Pain Ther，2022，11（2）：701-712．
本文引用 [1]
31
Croop R， Goadsby PJ， Stock DA，et al. Efficacy，safety，and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine：a randomised，phase 3，double-blind，placebo-controlled trial[J]. Lancet，2019，394（10200）：737-745．
本文引用 [2]
32
Dodick DW， Lipton RB， Ailani J，et al. Ubrogepant for the treatment of migraine[J]. N Engl J Med，2019，381（23）：2230-2241．
本文引用 [1]
33
Lipton RB， Croop R， Stock EG，et al. Rimegepant，an oral calcitonin gene-related peptide receptor antagonist，for migraine[J]. N Engl J Med，2019，381（2）：142-149．
34
Lipton RB， Dodick DW， Ailani J，et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine：the ACHIEVE Ⅱ randomized clinical trial[J]. JAMA，2019，322（19）：1887-1898．
本文引用 [1]
35
Blumenfeld AM， Goadsby PJ， Dodick DW，et al. Efficacy of ubrogepant based on prior exposure and response to triptans：a post hoc analysis[J]. Headache，2021，61（3）：422-429．
本文引用 [1]
36
Lipton RB， Blumenfeld A， Jensen CM，et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience：Pooled results from three phase 3 randomized clinical trials[J]. Cephalalgia，2023，43（2）：3331024221141686．
本文引用 [1]
37
Yang LPH. Sumatriptan/naproxen sodium：a review of its use in adult patients with migraine[J]. Drugs，2013，73（12）：1339-1355．
本文引用 [1]
38
Syed YY. Sumatriptan/naproxen sodium：a review in migraine[J]. Drugs，2016，76（1）：111-121．
本文引用 [1]
39
Brandes JL， Kudrow D， Stark SR，et al. Sumatriptan-naproxen for acute treatment of migraine：a randomized trial[J]. JAMA，2007，297（13）：1443-1454．
本文引用 [1]
40
Mathew NT， Landy S， Stark S，et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life[J]. Headache，2009，49（7）：971-982．
本文引用 [1]
41
Buse DC， Greisman JD， Baigi K，et al. Migraine progression：a systematic review[J]. Headache，2019，59（3）：306-338．
本文引用 [1]
42
Xu JJ， Kong FY， Buse DC. Predictors of episodic migraine transformation to chronic migraine：a systematic review and meta-analysis of observational cohort studies[J]. Cephalalgia，2020，40（5）：503-516．
本文引用 [1]
43
Katsarava Z， Schneeweiss S， Kurth T，et al. Incidence and predictors for chronicity of headache in patients with episodic migraine[J]. Neurology，2004，62（5）：788-790．
本文引用 [1]
44
Schwedt TJ， Alam A， Reed ML，et al. Factors associated with acute medication overuse in people with migraine：results from the 2017 migraine in America symptoms and treatment（MAST） study[J]. J Headache Pain，2018，19（1）：38．
本文引用 [1]
45
Lipton RB， Fanning KM， Serrano D，et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine[J]. Neurology，2015，84（7）：688-695．
本文引用 [2]
46
Bigal ME， Serrano D， Buse D，et al. Acute migraine medications and evolution from episodic to chronic migraine：a longitudinal population-based study[J]. Headache，2008，48（8）：1157-1168．
本文引用 [1]
47
Lipton RB， Serrano D， Nicholson RA，et al. Impact of NSAID and Triptan use on developing chronic migraine：results from the American migraine prevalence and prevention（AMPP） study[J]. Headache，2013，53（10）：1548-1563．
本文引用 [1]
48
Scher AI， Lipton RB， Stewart WF，et al. Patterns of medication use by chronic and episodic headache sufferers in the general population：results from the frequent headache epidemiology study[J]. Cephalalgia，2010，30（3）：321-328．
本文引用 [1]
49
Bigal ME， Lipton RB. Excessive acute migraine medication use and migraine progression[J]. Neurology，2008，71（22）：1821-1828．
本文引用 [1]
50
Barreto T. Acute treatments for episodic migraine in adults[J]. Am Fam Physician，2021，104（5）：509-512．
本文引用 [1]

Comments

PDF(518 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉